Curated News
By: NewsRamp Editorial Staff
July 11, 2025
SeaStar Medical's QUELIMMUNE Wins NKF's 2025 Corporate Innovator Award
TLDR
- SeaStar Medical's QUELIMMUNE device offers a competitive edge by significantly reducing mortality rates in pediatric AKI patients, showcasing innovation in nephrology.
- QUELIMMUNE works by targeting the cytokine storm in pediatric AKI patients, connecting to an existing CKRT circuit to regulate the immune response effectively.
- QUELIMMUNE improves pediatric AKI treatment outcomes, reducing mortality and long-term dialysis dependency, making a profound impact on children's health and future well-being.
- SeaStar Medical's QUELIMMUNE, awarded by the National Kidney Foundation, represents a breakthrough in treating pediatric AKI, with a 77% mortality rate reduction.
Impact - Why it Matters
The recognition of SeaStar Medical's QUELIMMUNE device by the National Kidney Foundation underscores a significant advancement in treating pediatric acute kidney injury, a condition with high mortality rates. This development is crucial for families and healthcare providers, offering hope for reducing deaths and long-term complications in affected children. Moreover, the ongoing expansion of QUELIMMUNE's application to adult AKI patients could revolutionize kidney disease treatment, addressing a widespread but often undiagnosed condition affecting millions.
Summary
SeaStar Medical (NASDAQ: ICU) has been honored with the 2025 Corporate Innovator Award by the National Kidney Foundation (NKF) for its groundbreaking QUELIMMUNE device, a treatment for pediatric acute kidney injury (AKI) due to sepsis. This recognition places SeaStar among esteemed past recipients like Janssen Pharmaceuticals and Merck & Co. Inc., highlighting the device's potential to significantly reduce mortality rates and improve quality of life for affected children. QUELIMMUNE, approved under a Humanitarian Device Exemption by the FDA, targets the cytokine storm in pediatric AKI patients, showing a 77% reduction in mortality and no dialysis dependency after 60 days in clinical trials. The NKF's award underscores SeaStar's contribution to addressing a critical unmet need in nephrology, with ongoing trials to extend QUELIMMUNE's benefits to adult AKI patients.
The National Kidney Foundation's 75-year legacy of advocating for kidney health, including the establishment of the Medicare ESRD benefit, complements SeaStar's mission. With over 35 million U.S. adults estimated to have kidney disease, the collaboration between innovative medical technology and foundational advocacy represents a beacon of hope for patients and families affected by kidney disease. SeaStar's achievement with QUELIMMUNE not only marks a significant milestone in pediatric nephrology but also sets the stage for future advancements in kidney care.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, SeaStar Medical's QUELIMMUNE Wins NKF's 2025 Corporate Innovator Award
